Evidence map›Paper›PMID 33977849›Full record

ReviewExpert opinion on biological therapy2021

The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission.

Jessica Kopenhaver, Madison Crutcher, Scott A Waldman, Adam E Snook

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on biological therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Emerging drug targets for colon cancer: A preclinical assessment.Expert opinion on therapeutic targets · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jessica KopenhaverDepartment of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, United States.
Madison CrutcherDepartment of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, United States.
Scott A WaldmanDepartment of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, United States.
Adam E SnookDepartment of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, United States.ORCID 0000-0001-9216-4560
Thomas Jefferson University · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM008562 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI WALTER K KRAFT, Scott A. Waldman · 1995 to 2026
$10.2M
Guanylin GUCY2C axis in Colorectal Cancer InitiationR01CA204481 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2017 to 2021
$1.8M
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformationR01CA206026 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2016 to 2020
$1.8M
NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA204481NCI NIH HHS R01 CA206026NIGMS NIH HHS T32 GM008562
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Colorectal NeoplasmsNeoplasm Recurrence, LocalHumansImmunotherapyMolecular Targeted TherapyNeoplastic Stem CellsReceptors, EnterotoxinGUCY2C protein, humanReceptors, Enterotoxincancer stem cellColorectal cancerguanylate cyclase cimmunotherapy

Identifiers

PMID33977849
PMCPMC8455440
OpenAlexW3162369269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.